Pentraxin-3 – a potential biomarker in ANCA-associated vasculitis

Abstract

Objective

The aim of this study was to investigate pentraxin-3 (PTX3) as a potential biomarker of inflammatory activity in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) at baseline and 6 month follow-up in a longitudinal cohort.

Method

Plasma PTX3 levels were measured in 79 newly diagnosed or relapsing AAV patients at baseline and 6 month follow-up, and in 23 healthy controls. Urinary PTX3 levels were measured in 34 of the patients. C-reactive protein (CRP), creatinine, and albuminuria were measured and the cumulative glucocorticoid dose at inclusion was calculated. The Birmingham Vasculitis Activity Score (BVAS) was assessed at baseline and follow-up.

Results

Plasma PTX3 levels were significantly higher at baseline than at 6 months (2.85 vs 1.23 ng/mL, p < 0.001). Plasma and urinary PTX3 levels correlated with BVAS at baseline (ρ = 0.45, p < 0.001, and ρ = 0.49, p = 0.008, respectively). A significant correlation between both plasma and urinary PTX3 levels and estimated glomerular filtration rate and albuminuria was found. However, there was no correlation between plasma and urinary PTX3 levels. At baseline, plasma and urinary PTX3 levels were significantly higher in patients with kidney involvement. PTX3 levels did not correlate with CRP, nor was there a correlation between CRP levels and BVAS at baseline.

Conclusion

Plasma and urinary PTX3 seem to reflect disease activity in AAV better than the commonly used CRP. PTX3 may have a potential role as a biomarker in monitoring disease activity in AAV patients, particularly in patients with kidney involvement.

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of necrotizing vasculitides that predominantly affect small to medium-sized vessels (1). Clinical manifestations vary widely, from a limited form restricted to the upper respiratory tract to a severe generalized disease with vital organ failure (2). Kidney involvement occurs in approximately 80–90% of patients and can lead to end-stage kidney disease (3). Untreated disease carries a 1 year mortality of around 80% (4). Although treatment options have improved, there are still no fully reliable methods available for monitoring disease activity, predicting relapse, and guiding individual treatment. It is thus essential to identify biomarkers that could enable tailored individual treatment, thwart relapses, and potentially reduce adverse treatment effects.

The pathogenesis of AAV is complex and not fully understood. Primed neutrophils are activated by ANCA and activated neutrophils undergo NETosis, a form of cell death with degranulation, respiratory burst, and release of neutrophil extracellular traps (NETs) (5–9). The formation of NETs and release of reactive oxygen species from activated neutrophils leads to endothelial damage (7). NETs induced by ANCA have been shown to activate the alternative complement pathway (10), which, in turn, leads to the generation of C5a, which is believed to play a role in the priming of neutrophils. This causes an inflammatory amplification loop that contributes to the pathogenesis of AAV (11).

Pentraxin-3 (PTX3) is a protein structurally similar to the short pentraxin C-reactive protein (CRP). In contrast to CRP, which is mainly produced in the liver, PTX3 is widely produced by a variety of cells, including dendritic cells, macrophages, vascular endothelial cells, and kidney epithelial cells, in response to various inflammatory stimuli. It is believed to reflect local tissue inflammatory activity more closely than CRP (12, 13).

PTX3 is a soluble pattern recognition receptor (14) that has the capacity to recognize a number of different ligands, including extracellular matrix proteins, apoptotic cells, pathogens, and complement components (12, 14). It has been shown to contribute to complement activation as well as regulation (15–19). Moreover, neutrophils store vast amounts of PTX3 in granules, which is released upon inflammatory stimulation and can be found in NETs (20), and PTX3 also appears to have a regulatory role on NETs (21). In addition, PTX3 affects the glycosylation-dependent regulation of inflammation and dampens neutrophil recruitment (22). As the alternative complement pathway and NET formation are believed to play an important part in the pathogenesis of AAV (5), PTX3 may be an interesting candidate biomarker in AAV patients.

Previous cross-sectional studies have assessed the PTX3 levels in AAV patients and found that the levels were higher in patients with active disease compared with inactive patients and healthy controls (23–25).

To the best of our knowledge, this is the first longitudinal study to investigate PTX3 levels in patients with AAV in relation to the disease activity and immunosuppressive treatment. Our aim was to further delineate the evolution and potential role of PTX3 as a biomarker in a longitudinal cohort of AAV patients.

Method

Patients and methods

Seventy-nine patients with active AAV were included in the study and followed prospectively. Samples from 23 healthy controls were obtained for comparison. Disease activity was assessed using the Birmingham Vasculitis Activity Score 2003 (BVAS) at baseline and at the 6 month follow-up (26). Disease remission was defined as a BVAS of 0. Kidney involvement was defined as kidney biopsy findings consistent with pauci-immune vasculitis or as a clinical presentation with affected kidney function and/or significant haematuria (defined as ≥ 2 on dipstick urinalysis or ≥ 10 erythrocytes per high-power field on urinary sediment).

The cumulative glucocorticoid (GC) dose that patients had received at the baseline sampling was calculated in prednisolone-equivalent milligrams (mg). For the patients with a relapse, the GC dose was calculated from the relapse diagnosis, when a higher dose was restarted. Low doses (up to 10 mg) given before the diagnosis of a relapse were not included in the analysis. The GC dose at the time of the 6 month follow-up was also registered.

The study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the local ethics committee, the Regional Ethical Review Board in Stockholm, and the Swedish Ethical Review Authority. Informed written consent was obtained from all participants.

Laboratory analysis

Peripheral venous blood (heparin plasma) samples and urine samples were obtained from patients at baseline and at the 6 month follow-up. Samples were frozen within 4 h and stored at −70°C for future analysis. Serum CRP and plasma creatinine were measured, and urine analysis was performed using routine methods at the Department of Clinical Chemistry at the Karolinska University Hospital. Albuminuria was assessed with morning urine albumin to creatinine ratio (mg/mmol), and estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (27). ANCA serology was analysed with an enzyme-linked immunosorbent assay (ELISA) (direct EliA; EURO Diagnostic, Malmö, Sweden) or multiplex (BioPlex TM 2200; Bio-Rad, Hercules, California, USA) according to clinical routine at the Department of Clinical Immunology at Karolinska University Hospital. Plasma and urinary levels of PTX3 were analysed using a commercially available ELISA kit from R&D Systems Europe (Abingdon, UK). The urinary pentraxin-3 to creatinine ratio (uPTX3/Cr) was calculated (ng/mmol).

Statistics

Normally distributed variables are presented as mean and standard deviation (sd), non-normally distributed variables as median and 25th to 75th percentiles, and categorical values as frequency and percentage. The Shapiro–Wilk test was used to examine distributions. The non-parametric Wilcoxon rank-sum test was used to assess the difference between two groups. The Wilcoxon signed-rank test was used for comparison over time and Kruskal–Wallis analysis of variance (ANOVA) for differences between time points and controls. Fisher’s exact test was used for comparison of categorical data. Correlations were calculated using the non-parametric Spearman rank test. To assess the prognostic value of baseline PTX3 in predicting kidney function at 6 months, receiver operator characteristics (ROC) curve analysis was performed. Statistical significance was set at the level of p < 0.05. Statistical analyses were performed with JMP software (version 14; SAS, Cary, NC, USA) and GraphPad Prism (version 9; GraphPad Software, La Jolla, CA, USA).

Results

Patients and controls

Seventy-nine patients with active AAV were included in the study and followed prospectively from baseline to a 6 months follow-up (median 195 days from inclusion). Forty-three were men and 36 women, with a median age of 58 years (age range 19–86 years). Seventy patients had a newly diagnosed disease and nine had a relapse of a previously diagnosed AAV. Fifty-four patients were diagnosed with granulomatosis with polyangiitis (GPA), 21 with microscopic polyangiitis (MPA), and four with eosinophilic granulomatosis with polyangiitis (EGPA). All patients were ANCA positive, 48 patients were positive for proteinase-3 (PR3) ANCA and 31 for myeloperoxidase (MPO) ANCA.

Twenty-three randomly selected healthy controls from the Swedish Population Registry, described in a previous study (28), were included for comparison. The baseline characteristics of the patients and controls are given in Table 1.

Table 1. Characteristics of patients and controls at baseline.

	Controls (n = 23)	AAV (n = 79)	p
Age (years), median (range)	63.0 (58.0–74.0)	58.0 (49.0–69.0)	0.032
Gender, male	12 (52)	43 (54)	0.85
ANCA
PR3		48 (60.8)
MPO		31 (39.2)
Diagnosis
GPA		54 (68.4)
MPA		21 (26.6)
EGPA		4 (5.0)
New diagnosis		70 (88.6)
Relapse		9 (11.4)
Kidney involvement		47 (59.5)
Treatment prior to inclusion
GCs		72 (91.1)
i.v. GCs		34 (43.0)
Median GC dose at baseline (mg)		60 (40–70)
Cumulative GC dose at baseline (mg)		625 (160–1875)
Cyclophosphamide		25 (31.6)
Rituximab		3 (3.8)
Methotrexate		7 (8.9)
Mycophenolate mofetil		2 (2.5)
Induction treatment
Cyclophosphamide		49 (62.0)
Rituximab		15 (18.9)
Methotrexate		13 (16.4)
Mycophenolate mofetil		5 (6.3)

Data are shown as n (%) or median (25th–75th percentiles), unless otherwise indicated.

Wilcoxon signed-rank test for continuous variables and Fisher’s exact test for nominal variables.

ANCA, anti-neutrophil cytoplasmic antibody; PR3, proteinase-3; MPO, myeloperoxidase; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; EGPA, eosinophilic granulomatosis with polyangiitis; GC, glucocorticoid.

Induction treatment

All but eight patients were included and sampled after the onset of treatment (median 5 days, range 0–37). All patients received treatment with GCs. Thirty-seven (46.8%) of the patients had received induction remission treatment with cyclophosphamide (CYC), rituximab (RTX), mycophenolate mofetil (MMF), or methotrexate (MTX) at the time of inclusion. The majority of these patients had recently started treatment with CYC (n = 25), but only one patient had received two doses of intravenous CYC before inclusion. Two patients received high-dose GCs only owing to localized ear, nose, and throat (ENT) involvement. The remainder of the patients received induction treatment after inclusion, as shown in Table 1.

Maintenance treatment

At the 6 month follow-up, 58 of the patients had started maintenance treatment with azathioprine (AZA), MMF, RTX, or MTX in combination with a low dose of GCs.

Disease activity and phenotype

Disease activity measured as BVAS decreased from a median of 15 at baseline to a median of 0 at the 6 month follow-up (p < 0.001) (Table 2). Forty-seven patients had kidney involvement at baseline, 43 confirmed with kidney biopsy and four patients diagnosed clinically. A failure to achieve complete remission of disease activity (BVAS > 0) was seen in five out of 79 patients at follow-up. All of these patients had ENT involvement, two had lung involvement, but none had active kidney disease.

Table 2. Birmingham Vasculitis Activity Score (BVAS) and laboratory analysis at baseline and at 6 month follow-up.

Variable	Baseline	6 months	p||
BVAS	15 (10–21)	0 (0–0)	< 0.0001
Plasma creatinine (µmol/L)	87.0 (69.0–170.0)	91.5 (80.0–127.0)	0.98
eGFR (mL/min/1.73 m^2)*	74.5 (34.1–102.4)	68.3 (38.8–89.0)	0.08
Serum CRP (mg/L)†	9.0 (2.0–27.0)	2.0 (0.0–5.0)	< 0.0001
Haematuria, n (%)‡	44 (56.4)	12 (16.0)	< 0.001
UACR (mg/mmol)	12.3 (0.9–37.0)	3.9 (0.6–24.3)	< 0.001
Plasma PTX3 (ng/mL)	2.9 (1.4–5.9)	1.2 (0.88–1.78)	< 0.0001
Urinary PTX3 (pg/mL)§	11.0 (0–68.5)	0 (0–11.0)	0.01
Urinary PTX3 to creatinine ratio (ng/mmol)	0.8 (0–12.6)	0 (0–1.0)	0.01

Data are shown as median (25th–75th percentiles) unless otherwise indicated.

eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; UACR, urine albumin to creatinine ratio; PTX3, pentraxin-3.

*Calculated using the CKD-EPI equation.

†CRP normal reference range < 3 mg/L.

‡Haematuria was defined as ≥ 2 on urine dipstick or > 10 erythrocytes/high-power field on urine sediment. Urine analysis and/or urine sediment was available for 78 patients at baseline and 75 patients at follow-up.

§Urinary PTX3 levels were available for 34 patients at baseline and 33 patients at 6 months.

||Wilcoxon signed-rank test for continuous variables and Fisher’s exact test for nominal variables.

Laboratory results

Plasma PTX3 levels

The plasma PTX3 levels in patients were significantly higher at baseline than at follow-up (median 2.85 vs 1.23 ng/mL, p < 0.001, Wilcoxon signed-rank test). Levels were also significantly higher at baseline and at 6 months in AAV patients compared to controls (p < 0.001, non-parametric ANOVA Kruskal–Wallis H-test) (Figure 1 and Table 2). Plasma PTX3 levels correlated with BVAS at baseline (ρ = 0.45, p < 0.001). All except five patients were in remission at the follow-up, and no significant difference in PTX3 plasma levels was found between patients in remission and those with active disease (1.25 ng/mL vs 0.75 ng/mL, p = 0.13). The results are shown in Table 3 and Figure 2. PTX3 levels at baseline were higher in patients with newly diagnosed disease than in patients with relapsing disease (p = 0.046, Wilcoxon rank-sum test).

Table 3. Spearman rank correlation coefficients between plasma pentraxin-3 (PTX3) and clinical and laboratory variables at baseline.

Variable	ρ	p
BVAS	0.45	< 0.0001
CRP (mg/L)	0.13	0.25
Creatinine (µmol/L)	0.38	< 0.001
eGFR (mL/min/1.73 m^2)*	−0.41	< 0.001
UACR (mg/mmol)	0.44	< 0.0001
uPTX3 (pg/mL)	0.17	0.34
uPTX3 to creatinine ratio (ng/mmol)	0.23	0.23
Cumulative GC dose (mg)†	0.37	< 0.001

BVAS, Birmingham Vasculitis Activity Score; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; UACR, urine albumin to creatinine ratio; uPTX3, urinary pentraxin-3; GC, glucocorticoid.

*Calculated using the Chronic Kidney Disease Epidemiology Collaboration equation.

†Prednisolone-equivalent milligrams.

Figure 1. Plasma pentraxin-3 (PTX3) levels in patients at baseline and at the 6 month follow-up compared to controls. Non-parametric analysis of variance Kruskal–Wallis H-test followed by Dunn’s test.

Figure 2. Correlation between Birmingham Vasculitis Activity Score (BVAS) and (A) C-reactive protein (CRP), (B) plasma pentraxin-3 (PTX3), and (C) urinary PTX3 to creatinine ratio at baseline. Spearman correlation coefficient.

Urinary PTX3 levels

Urine samples for PTX3 analysis were available in a subset of the patients, 34 patients at baseline and 33 at follow-up. uPTX3/Cr could be calculated in 28 patients at baseline and 31 at follow-up, 26 of whom were available at both time points for comparison over time. Levels of uPTX3/Cr were significantly higher at baseline than at follow-up (p = 0.01, Wilcoxon signed-rank test) (Figure 3). A significant correlation was found between uPTX3/Cr and BVAS at baseline (ρ = 0.49, p = 0.008) (Figure 2). At follow-up, there was no significant difference in urinary PTX3 levels between patients in remission and those with active disease. No significant correlation was found between plasma PTX3 levels and the uPTX3/Cr at baseline (Table 3).

Figure 3. Urinary pentraxin-3 (PTX3) to creatinine ratio at baseline and at the 6 month follow-up. Wilcoxon signed-rank test. **p = 0.01.

PTX3 levels and kidney involvement

Plasma and urinary PTX3 levels were significantly higher in patients with kidney involvement at baseline compared to those without (p = 0.001 and p = 0.005, respectively, Wilcoxon rank-sum test). Moreover, a significant correlation was found between plasma PTX3 and creatinine, eGFR, and albuminuria at baseline, but not at 6 months (Table 3). Similarly, significant correlations were found between uPTX3/Cr and eGFR (ρ = −0.42, p = 0.025) and between uPTX3/Cr and albuminuria at baseline (ρ = 0.54, p = 0.002), but no significant correlation was found at 6 months (Table 3).

CRP levels

CRP decreased from a median of 9.0 mg/L at baseline sampling to 2.0 mg/L at the 6 month follow-up (p < 0.001, Wilcoxon signed-rank test) (Table 2). However, PTX3 levels did not significantly correlate with CRP, and there was no significant correlation between CRP levels and BVAS at baseline (Table 3 and Figure 2). There was also no significant difference in CRP levels between patients with and those without kidney involvement or between patients with relapse and patients with a new diagnosis.

Treatment and PTX3 levels

Patients who had received induction treatment at inclusion (n = 71) had significantly higher plasma PTX3 levels than treatment-naïve patients (n = 8) (3.15 vs 1.35 ng/mL, p = 0.03, Wilcoxon rank-sum test). No significant difference in urinary PTX3 levels between these groups was found.

Plasma PTX3 levels correlated significantly with the cumulative GC dose given at baseline (ρ = 0.37, p < 0.001). In contrast, there was a negative correlation between CRP and the cumulative GC dose (ρ = −0.31, p < 0.01). There was also a significant correlation between the GC dose at baseline and plasma PTX3 levels (ρ = 0.43, p < 0.0001). However, a significant correlation between uPTX3/Cr and the GC dose at baseline or the cumulative GC dose at baseline was not found.

We found no significant correlation between plasma PTX3 or CRP levels and GC dose at 6 months.

There was no significant difference in plasma or urinary PTX3 levels between patients who had received CYC at baseline and those who had not, and no correlation was found between CYC dose given at baseline and plasma PTX3 levels. No difference was found between patients who had received treatment with methotrexate (n = 7) at baseline and those who had not. As only very few patients had received RTX (n = 2) and MMF (n = 2), no analysis was conducted for comparison for these groups.

Predictive role of PTX3

ROC curve analysis was performed to assess whether PTX3 could be a potential prognostic marker for kidney function (eGFR) at the 6 month follow-up. The area under the curve was 0.62 (data not shown).

Discussion

The identification of novel inflammatory markers that more closely reflect disease activity and specific organ involvement in patients with AAV is an unmet need. In this study, we found increased plasma PTX3 levels in active AAV compared to inactive disease and healthy controls, and a decrease following immunosuppressive therapy. Similarly, urinary PTX3 levels were higher in patients with active disease than in those in remission, and correlated with disease activity (indicated by BVAS). Our findings are consistent with the results of our previous cross-sectional study, where we found higher levels of circulating PTX3 as well as PTX3 expressed on circulating microparticles in patients with active AAV disease compared to inactive disease and controls (25). In this study, we could also show that circulating PTX3 levels did not correlate with CRP, nor was there a correlation between CRP levels and BVAS at baseline.

PTX3 is a long pentraxin that is produced by various cells in response to inflammatory signals and therefore is believed to reflect local tissue inflammatory activity and immune responses (12, 13). PTX3 is stored in granules in neutrophils and released to NETs on stimulation (20). PTX3 has been shown to increase in inflammatory diseases, and also in other inflammatory conditions such as infections and myocardial infarction (29–31). The fact that neutrophils and NET formation play an important role in the pathogenesis of AAV suggests that PTX3 may be a potential biomarker in these diseases.

In contrast to levels of the commonly used inflammatory marker CRP, plasma PTX3 correlated with disease activity (BVAS), implying that PTX3 may be a more dependable biomarker for monitoring disease activity in AAV. Our results are also in line with previous reports on diabetic nephropathy and systemic lupus erythematous (SLE), which showed a better correlation between the disease activity and the plasma PTX3 levels compared to CRP (32, 33). Furthermore, several studies on patients with various systemic inflammatory and cardiovascular diseases have failed to show a significant correlation between CRP and PTX3 (30, 33–38), including a previous cross-sectional study of 43 AAV patients (23).

We are not convinced that PTX3 is a better disease marker than BVAS, which, so far, has been the gold standard for assessing disease activity in AAV in research and clinical trials. However, BVAS is rarely used in clinical settings, which would make more readily available biomarkers more useful. However, as reliable biomarkers in AAV are lacking, our study suggests that PTX3 may have a role here. Our results show that it correlates with disease activity and, furthermore, is a better disease activity marker than the commonly used CRP.

Besides the association with disease activity, there was a correlation between both plasma and urinary PTX3 levels and albuminuria and kidney function. Furthermore, higher plasma and urinary PTX3 levels were seen among patients with kidney involvement, also suggesting a potential role in AAV kidney pathogenesis. A possible explanation for elevated plasma PTX3 levels in patients with impaired kidney function is retention caused by decreased kidney clearance. PTX3 (42 kDa) forms multimers that are approximately 440 kDa in size (16), which could affect its clearance. This has been suggested by previous studies demonstrating elevated plasma PTX3 levels in patients with chronic kidney disease (39, 40). However, our results show that urinary PTX3 levels were elevated in patients with kidney involvement. No correlation was found between plasma PTX3 levels and urinary PTX3 levels. The reason for this is unclear and, furthermore, urine samples were only available in a subset of patients. Even though our results indicate that both plasma and urinary PTX3 may be potentially useful and possibly independent disease activity markers in AAV, further longitudinal studies are required to determine the optimal use of PTX3 in plasma and urine as a potential biomarker reflecting disease activity in AAV patients with or without kidney involvement. In addition, even though the baseline plasma PTX3 level did reflect disease activity, it did not seem to predict damage, as reflected by kidney function, in the short 6 month follow-up period.

Previously, urinary PTX3 has mainly been studied in relation to urinary tract infections and the results have indicated that PTX3 in urine may play a role in the innate immune defence against pathogens in the urinary tract (41). Furthermore, elevated urinary PTX3 levels have been found in patients with kidney scars following pyelonephritis (42). This suggests that there is increased local production of PTX3 during inflammation in the kidney and the urinary tract, independent of systemic PTX3 levels. Hence, urinary PTX3 may reflect local kidney inflammation better than the plasma levels. Supporting this hypothesis are findings demonstrating that PTX3 is expressed in kidney tissue in patients with immunoglobulin A nephropathy (IgAN), type 1 membranoproliferative glomerulonephritis, and lupus nephritis (LN) (43, 44). PTX3 was shown to be expressed in the glomeruli, on infiltrating inflammatory cells in the peritubular capillaries, and in the kidney interstitium in IgAN (43), as well as in the tubulointerstitial area in patients with active LN (43, 44). Moreover, urinary PTX3 levels have been shown to be elevated in patients with active LN compared to those with inactive disease and healthy controls (44).

Animal model studies have previously demonstrated that PTX3 may have a role in limiting acute and chronic kidney injury (45). This may indicate that PTX3 influences several compartments within the kidney and potentially also has a protective role by controlling inflammation depending on the pathophysiological conditions. However, studies are needed to delineate these mechanisms in AAV, particularly in patients with kidney involvement where tissue samples are available for further analysis.

We found a positive correlation between plasma PTX3 levels and the cumulative dose of GCs at baseline. Similar results have been shown in patients with SLE, where a significant correlation was shown between PTX3 levels and the prednisolone dose (33). One possible explanation is that patients requiring higher doses have more severe disease, and therefore plasma PTX3 may reflect disease activity better than the dose of GC given. In contrast, CRP was negatively correlated with the cumulative GC dose given at baseline, which suggests that CRP kinetics may differ by being more readily affected by GC treatment. Another possible explanation is that the high-dose GC treatment could increase the circulating PTX3 levels. In line with this hypothesis, PTX3 levels have been shown to increase with intravenous GC treatment and to be elevated in patients with Cushing’s syndrome. Doni et al also showed that GCs had different effects in different cell types, inducing PTX3 gene expression in non-haematopoietic cells and repressing it in haematopoietic cells (46). Plasma PTX3 levels were also higher in patients who had received induction treatment than in those who were treatment naïve at sampling. These findings can probably be explained by more severe disease activity in this group compared to those who had not yet received treatment.

A strength of our study is having access to both baseline information and prospective follow-up samples combined with clinical data. Furthermore, patients with various organ manifestations, ranging from localized ENT symptoms to serious disease with multi-organ involvement, were included. Limitations include the lack of further follow-up after 6 months, which could have contributed to a better understanding of PTX3 as a potential predictor of relapse. Another limitation is that the majority of patients were not treatment naïve, as most had started induction treatment owing to pressing clinical needs, before inclusion in the study. We tried to address this by examining the effects of the administered GC doses and immunosuppressive therapy on PTX3 levels at inclusion.

Conclusion

Plasma and urinary PTX3 levels were significantly increased in active AAV disease, and in particular in patients with kidney involvement. Furthermore, both plasma and urinary PTX3 levels seem to reflect disease activity in active AAV better than the commonly used CRP. GC doses may possibly affect the PTX3 levels, but this relationship needs to be explored further. Plasma and urinary PTX3 may have a role in AAV pathogenesis, and PTX3 could be a potential new biomarker in AAV. Future studies should include long-term follow-up to assess whether PTX3 may also have a role in detecting AAV relapses at an early stage.

Disclosure Statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This work was supported by the The Swedish Kidney Foundation [F2019-0056, F2018-0045]; The Swedish Renal Fund [2019]; the Stockholm County Council [SLL20180104, SLL20200277].